{
    "id": 23777,
    "fullName": "TRIB2 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "TRIB2 over exp indicates an over expression of the Trib2 protein and/or mRNA. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 28951,
        "geneSymbol": "TRIB2",
        "terms": [
            "TRIB2",
            "C5FW",
            "GS3955",
            "TRB2"
        ]
    },
    "variant": "over exp",
    "createDate": "06/27/2016",
    "updateDate": "11/19/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7147,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3039478 and NSC156529 combination treatment resulted in improved growth inhibition over single drug treatment in primary liver cancer cells over expressing target genes of the Notch (HES1, HEY1, TRIB2, NOTCH3, CCND1) and Hedgehog (GLI1, GLI2) pathways in culture (PMID: 27103434).",
            "molecularProfile": {
                "id": 24497,
                "profileName": "CCND1 over exp GLI1 over exp GLI2 over exp HES1 over exp HEY1 over exp NOTCH3 over exp TRIB2 over exp"
            },
            "therapy": {
                "id": 4383,
                "therapyName": "LY3039478 + NSC156529",
                "synonyms": null
            },
            "indication": {
                "id": 3571,
                "name": "liver cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6106,
                    "pubMedId": 27103434,
                    "title": "The inhibition of Akt-Pdpk1 interaction efficiently suppresses the growth of murine primary liver tumor cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27103434"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7144,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PNU-74654 did not inhibit growth of primary liver cancer cells over expressing target genes of the Notch (HES1, HEY1, TRIB2, NOTCH3, CCND1) and Hedgehog (GLI1, GLI2) pathways in culture (PMID: 27103434).",
            "molecularProfile": {
                "id": 24497,
                "profileName": "CCND1 over exp GLI1 over exp GLI2 over exp HES1 over exp HEY1 over exp NOTCH3 over exp TRIB2 over exp"
            },
            "therapy": {
                "id": 2454,
                "therapyName": "PNU-74654",
                "synonyms": null
            },
            "indication": {
                "id": 3571,
                "name": "liver cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6106,
                    "pubMedId": 27103434,
                    "title": "The inhibition of Akt-Pdpk1 interaction efficiently suppresses the growth of murine primary liver tumor cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27103434"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7146,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2334470 moderately inhibited growth of primary liver cancer cells over expressing target genes of the Notch (HES1, HEY1, TRIB2, NOTCH3, CCND1) and Hedgehog (GLI1, GLI2) pathways in culture (PMID: 27103434).",
            "molecularProfile": {
                "id": 24497,
                "profileName": "CCND1 over exp GLI1 over exp GLI2 over exp HES1 over exp HEY1 over exp NOTCH3 over exp TRIB2 over exp"
            },
            "therapy": {
                "id": 3662,
                "therapyName": "GSK2334470",
                "synonyms": null
            },
            "indication": {
                "id": 3571,
                "name": "liver cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6106,
                    "pubMedId": 27103434,
                    "title": "The inhibition of Akt-Pdpk1 interaction efficiently suppresses the growth of murine primary liver tumor cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27103434"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7142,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NSC156529 efficiently inhibited survival of primary liver cancer cells over expressing target genes of the Notch (HES1, HEY1, TRIB2, NOTCH3, CCND1) and Hedgehog (GLI1, GLI2) pathways in culture (PMID: 27103434).",
            "molecularProfile": {
                "id": 24497,
                "profileName": "CCND1 over exp GLI1 over exp GLI2 over exp HES1 over exp HEY1 over exp NOTCH3 over exp TRIB2 over exp"
            },
            "therapy": {
                "id": 4085,
                "therapyName": "NSC156529",
                "synonyms": null
            },
            "indication": {
                "id": 3571,
                "name": "liver cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6106,
                    "pubMedId": 27103434,
                    "title": "The inhibition of Akt-Pdpk1 interaction efficiently suppresses the growth of murine primary liver tumor cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27103434"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7143,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GANT61 did not inhibit growth of primary liver cancer cells over expressing target genes of the Notch (HES1, HEY1, TRIB2, NOTCH3, CCND1) and Hedgehog (GLI1, GLI2) pathways in culture (PMID: 27103434).",
            "molecularProfile": {
                "id": 24497,
                "profileName": "CCND1 over exp GLI1 over exp GLI2 over exp HES1 over exp HEY1 over exp NOTCH3 over exp TRIB2 over exp"
            },
            "therapy": {
                "id": 1786,
                "therapyName": "GANT61",
                "synonyms": null
            },
            "indication": {
                "id": 3571,
                "name": "liver cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6106,
                    "pubMedId": 27103434,
                    "title": "The inhibition of Akt-Pdpk1 interaction efficiently suppresses the growth of murine primary liver tumor cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27103434"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7145,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nutlin-3 moderately inhibited growth of primary liver cancer cells over expressing target genes of the Notch (HES1, HEY1, TRIB2, NOTCH3, CCND1) and Hedgehog (GLI1, GLI2) pathways in culture (PMID: 27103434).",
            "molecularProfile": {
                "id": 24497,
                "profileName": "CCND1 over exp GLI1 over exp GLI2 over exp HES1 over exp HEY1 over exp NOTCH3 over exp TRIB2 over exp"
            },
            "therapy": {
                "id": 1405,
                "therapyName": "Nutlin-3",
                "synonyms": null
            },
            "indication": {
                "id": 3571,
                "name": "liver cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6106,
                    "pubMedId": 27103434,
                    "title": "The inhibition of Akt-Pdpk1 interaction efficiently suppresses the growth of murine primary liver tumor cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27103434"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7141,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3039478 efficiently inhibited survival of primary liver cancer cells over expressing target genes of the Notch (HES1, HEY1, TRIB2, NOTCH3, CCND1) and Hedgehog (GLI1, GLI2) pathways in culture (PMID: 27103434).",
            "molecularProfile": {
                "id": 24497,
                "profileName": "CCND1 over exp GLI1 over exp GLI2 over exp HES1 over exp HEY1 over exp NOTCH3 over exp TRIB2 over exp"
            },
            "therapy": {
                "id": 2958,
                "therapyName": "LY3039478",
                "synonyms": null
            },
            "indication": {
                "id": 3571,
                "name": "liver cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6106,
                    "pubMedId": 27103434,
                    "title": "The inhibition of Akt-Pdpk1 interaction efficiently suppresses the growth of murine primary liver tumor cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27103434"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15224,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Dactolisib (BEZ235) treatment of transformed human kidney cells expressing Trib2 were resistant, as indicated by decreased cells in G1 phase and increased tumor volume in cell line xenografts (PMID: 28276427).",
            "molecularProfile": {
                "id": 24498,
                "profileName": "TRIB2 over exp"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 12870,
                    "pubMedId": 28276427,
                    "title": "TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28276427"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15223,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, small-cell lung carcinoma cell lines with overexpression of Trib2 were resistant to cisplatin (PMID: 29312632).",
            "molecularProfile": {
                "id": 24498,
                "profileName": "TRIB2 over exp"
            },
            "therapy": {
                "id": 700,
                "therapyName": "Cisplatin",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 12871,
                    "pubMedId": 29312632,
                    "title": "TRIB2 contributes to cisplatin resistance in small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29312632"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 24497,
            "profileName": "CCND1 over exp GLI1 over exp GLI2 over exp HES1 over exp HEY1 over exp NOTCH3 over exp TRIB2 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24498,
            "profileName": "TRIB2 over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}